Clinical Trials Logo

Catheter Ablation clinical trials

View clinical trials related to Catheter Ablation.

Filter by:

NCT ID: NCT06181578 Not yet recruiting - Catheter Ablation Clinical Trials

Ganglion Plexus Ablation in Persistent Atrial Fibrillation

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This study aims to investigate the long-term efficacy and safety of incorporating ganglionated plexus ablation into radiofrequency ablation strategies for persistent atrial fibrillation.

NCT ID: NCT06160076 Recruiting - Atrial Fibrillation Clinical Trials

Inflammatory Response Following " Pulsed Field Ablation " vs. Radiofrequency Ablation-2

RIPAF-2
Start date: October 16, 2023
Phase:
Study type: Observational

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Catheter ablation using pulmonary vein isolation (PVI) in an established treatment strategy for AF. Pulsed Field Ablation (PFA) is a non-thermal ablation modality which has recently been introduced in clinical practice with the aim of improving PVI efficacy and safety. The aim of this study is to analyse whether PFA generates a lower inflammatory reaction as compared to conventional radiofrequency ablation (RFA).

NCT ID: NCT06124690 Active, not recruiting - Clinical trials for Persistent Atrial Fibrillation

Persistent Atrial Fibrillation Without the Evidence of Low-voltage Areas

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

An effective therapy of persistent atrial fibrillation beyond pulmonary vein isolation remains unsatisfactory. Targeting endocardial low-voltage areas represents an approach of substrate modification. This prospective, randomized study investigated the efficacy of ablation of low-voltage areas versus PVI and additional linear ablations in patients with persistent atrial fibrillation in terms of single-procedure arrhythmia-free outcome and safety.

NCT ID: NCT06111443 Active, not recruiting - Catheter Ablation Clinical Trials

Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation

Start date: December 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this clinical trial is to test the effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation. The main questions it aims to answer are: • If Dapagliflozin will reduce the recurrence of all atrial tachyarrhythmias [atrial fibrillation (AF), atrial flutter (AFL) and atrial tachycardia (AT)] greater than 30 seconds during one-year follow-up after catheter ablation. Participants will receive Dapagliflozin (FORXIGA) 10 milligram (mg) once a day (QD) for 3 months after catheter ablation of atrial fibrillation. Researchers will compare patients who receive usual care to see if Dapagliflozin will reduce the recurrence of all atrial tachyarrhythmias (AF/AFL/AT) during one-year follow-up after catheter ablation.

NCT ID: NCT06096246 Not yet recruiting - Clinical trials for Persistent Atrial Fibrillation

Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF)

ORBICA-AF
Start date: April 5, 2024
Phase: N/A
Study type: Interventional

The main aim of the research is to investigate whether patients undergoing pulmonary vein isolation with catheter ablation for persistent atrial fibrillation (AF) will have lower rates of AF recurrence than those treated by DC cardioversion without an ablation procedure.

NCT ID: NCT05777850 Recruiting - Catheter Ablation Clinical Trials

High-Power Short-Duration Radiofrequency Ablation in Patients With Typical Atrial Flutter

FASD-HP
Start date: October 25, 2022
Phase: N/A
Study type: Interventional

The aim of cavotricuspid isthmus (CTI) dependent flutter ablation is the bidirectional conduction block of CTI. The probability of achieving a permanent bidirectional block at the CTI depends, mainly, on the ablation energy applied and the quality of the obtained lesion. Among the factors that determine the lesion's quality those which have the bigger impact are catheter stability, contact force, power and duration of energy application and the temperature reached at depth.This is a multicenter 1:1 randomized, blinded (open for the operator) study. Two CTI ablation strategies are compared: 1) conventional treatment branch which consists of individual 25-40 W applications of unlimited duration until achieving in each application the minimum value of one of the currently accepted and used lesion markers (Ablation Index >500 at the anterior half of the CTI and >400 at the posterior half with de CARTO 3 system; 2) experimental treatment branch consistent of CTI block using individual high power (90W) short duration (4 seconds) point-by-point applications. The main objective of this study is assessing the non-inferiority of the efficacy and safety of high-power short-duration ablation in patients undergoing typical atrial flutter ablation. Secondary objectives include the comparison of total radiofrequency time, number of applications, number of steam pops, percentage of reconnections, procedure duration, pain during the procedure and time to atrial flutter recurrence.

NCT ID: NCT05777551 Recruiting - Atrial Fibrillation Clinical Trials

AF Ablation With High Power Short Duration RF

AIR HPSD
Start date: January 1, 2023
Phase:
Study type: Observational [Patient Registry]

This is a prospective, multi-center, research study designed to evaluate the safety and efficacy of pulmonary vein (PV) isolation with high power short duration radiofrequency energy in patients with paroxysmal/persistent atrial fibrillation (AF). Subjects with paroxysmal/persistent AF will undergo catheter ablation using commercially approved devices (mapping system and catheters). Patients will be followed up for 12 months to measure the recurrence of AF and its predictors. The primary endpoint will be to investigate the association between clinical and procedural characteristics and the efficacy and the safety of PVI performed with HPSD. At least 850 consecutive will be enrolled to have an adequate statistical power for the analysis of the primary endpoint. We assume that the freedom form AF recurrence at 12 months will be 80%. Expected R^2 (Cox-Snell) 0.1. Candidate variables to be included in the model:10. Shrinkage level: 0.9. Based on these assumption the minimum number of patients is 850 with 170 events and EPP 17.

NCT ID: NCT05716581 Not yet recruiting - Atrial Fibrillation Clinical Trials

Prognostic Factors for Ablation of Atrial Fibrillation

Start date: March 1, 2023
Phase:
Study type: Observational

The aim of the study is to find factors associated with sinus rhythm maintenance after catheter ablation for atrial fibrillation.

NCT ID: NCT05575544 Not yet recruiting - Atrial Fibrillation Clinical Trials

Electroacupuncture Intervention in Catheter Ablation of Atrial Fibrillation

Start date: October 11, 2022
Phase: N/A
Study type: Interventional

This is a randomized control trial to determine whether electroacupuncture(EA) intervention with Morphine can reduce the intraoperative pain and early post-operative complications in patients undergoing catheter ablation of atrial fibrillation.

NCT ID: NCT05565183 Not yet recruiting - Clinical trials for Paroxysmal Atrial Fibrillation

Combined Study of ATrial Strain and Voltage by High Density Mapping in Young Patients With Atrial Fibrillation.

CATS-AF
Start date: October 2022
Phase: N/A
Study type: Interventional

Atrial The treatment of atrial fibrillation (AF) includes 2 axes: the prevention of the cardio-embolic risk and rhythm control. The possibilities for this control are antiarrhythmic drugs and, above all, catheter ablation, an interventional cardiology technique which consists in treating the areas responsible for the initiation and perpetuation of AF by applying radiofrequency energy or cryotherapy to the myocardial tissue. Limited research has been done on the combination of different parameters to manage AF, especially during the initial stage of the disease. A translational and multimodal approach could make it possible to better characterize this pathology and thus, help to adjust the therapeutic management for the patients. The combined analysis of regional electrophysiological, morphological, and functional parameters of the left atrium could make it possible to better detect early atrial cardiomyopathy and predict recurrences of atrial fibrillation.